vs
Side-by-side financial comparison of Intellia Therapeutics, Inc. (NTLA) and SANDRIDGE ENERGY INC (SD). Click either name above to swap in a different company.
SANDRIDGE ENERGY INC is the larger business by last-quarter revenue ($39.4M vs $23.0M, roughly 1.7× Intellia Therapeutics, Inc.). SANDRIDGE ENERGY INC runs the higher net margin — 54.9% vs -416.2%, a 471.1% gap on every dollar of revenue. On growth, Intellia Therapeutics, Inc. posted the faster year-over-year revenue change (78.8% vs 1.1%). SANDRIDGE ENERGY INC produced more free cash flow last quarter ($14.4M vs $-69.4M). Over the past eight quarters, SANDRIDGE ENERGY INC's revenue compounded faster (14.1% CAGR vs -10.8%).
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineere...
SandRidge Energy, Inc. is a company engaged in hydrocarbon exploration in the Mid-Continent region of the United States. It is organized in Delaware and headquartered in Oklahoma City, Oklahoma.
NTLA vs SD — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $23.0M | $39.4M |
| Net Profit | $-95.8M | $21.6M |
| Gross Margin | — | — |
| Operating Margin | -428.9% | 38.5% |
| Net Margin | -416.2% | 54.9% |
| Revenue YoY | 78.8% | 1.1% |
| Net Profit YoY | 25.7% | 23.1% |
| EPS (diluted) | $-0.81 | $0.59 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $23.0M | $39.4M | ||
| Q3 25 | $13.8M | $39.8M | ||
| Q2 25 | $14.2M | $34.5M | ||
| Q1 25 | $16.6M | $42.6M | ||
| Q4 24 | $12.9M | $39.0M | ||
| Q3 24 | $9.1M | $30.1M | ||
| Q2 24 | $7.0M | $26.0M | ||
| Q1 24 | $28.9M | $30.3M |
| Q4 25 | $-95.8M | $21.6M | ||
| Q3 25 | $-101.3M | $16.0M | ||
| Q2 25 | $-101.3M | $19.6M | ||
| Q1 25 | $-114.3M | $13.0M | ||
| Q4 24 | $-128.9M | $17.6M | ||
| Q3 24 | $-135.7M | $25.5M | ||
| Q2 24 | $-147.0M | $8.8M | ||
| Q1 24 | $-107.4M | $11.1M |
| Q4 25 | -428.9% | 38.5% | ||
| Q3 25 | -808.9% | 37.8% | ||
| Q2 25 | -772.2% | 53.7% | ||
| Q1 25 | -726.6% | 28.6% | ||
| Q4 24 | -1059.9% | 25.9% | ||
| Q3 24 | -1589.0% | 28.3% | ||
| Q2 24 | -1998.6% | 23.9% | ||
| Q1 24 | -394.0% | 27.8% |
| Q4 25 | -416.2% | 54.9% | ||
| Q3 25 | -735.2% | 40.1% | ||
| Q2 25 | -710.8% | 56.6% | ||
| Q1 25 | -687.6% | 30.6% | ||
| Q4 24 | -1001.2% | 45.1% | ||
| Q3 24 | -1489.5% | 84.8% | ||
| Q2 24 | -2112.6% | 33.9% | ||
| Q1 24 | -371.3% | 36.7% |
| Q4 25 | $-0.81 | $0.59 | ||
| Q3 25 | $-0.92 | $0.43 | ||
| Q2 25 | $-0.98 | $0.53 | ||
| Q1 25 | $-1.10 | $0.35 | ||
| Q4 24 | $-1.27 | $0.46 | ||
| Q3 24 | $-1.34 | $0.69 | ||
| Q2 24 | $-1.52 | $0.24 | ||
| Q1 24 | $-1.12 | $0.30 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $449.9M | $111.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $671.4M | $510.9M |
| Total Assets | $842.1M | $644.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $449.9M | $111.0M | ||
| Q3 25 | $511.0M | $101.2M | ||
| Q2 25 | $459.7M | $102.8M | ||
| Q1 25 | $503.7M | $99.7M | ||
| Q4 24 | $601.5M | $98.1M | ||
| Q3 24 | $658.1M | $92.7M | ||
| Q2 24 | $691.1M | $209.9M | ||
| Q1 24 | $791.3M | $207.0M |
| Q4 25 | $671.4M | $510.9M | ||
| Q3 25 | $748.4M | $492.4M | ||
| Q2 25 | $715.3M | $480.2M | ||
| Q1 25 | $779.9M | $464.9M | ||
| Q4 24 | $872.0M | $460.5M | ||
| Q3 24 | $962.6M | $446.8M | ||
| Q2 24 | $971.1M | $424.8M | ||
| Q1 24 | $1.0B | $419.7M |
| Q4 25 | $842.1M | $644.0M | ||
| Q3 25 | $925.3M | $619.0M | ||
| Q2 25 | $898.9M | $602.3M | ||
| Q1 25 | $986.2M | $588.3M | ||
| Q4 24 | $1.2B | $581.5M | ||
| Q3 24 | $1.2B | $565.2M | ||
| Q2 24 | $1.2B | $529.6M | ||
| Q1 24 | $1.3B | $527.4M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-69.3M | $31.7M |
| Free Cash FlowOCF − Capex | $-69.4M | $14.4M |
| FCF MarginFCF / Revenue | -301.6% | 36.6% |
| Capex IntensityCapex / Revenue | 0.5% | 43.8% |
| Cash ConversionOCF / Net Profit | — | 1.46× |
| TTM Free Cash FlowTrailing 4 quarters | $-395.9M | $41.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-69.3M | $31.7M | ||
| Q3 25 | $-76.9M | $25.3M | ||
| Q2 25 | $-99.6M | $22.9M | ||
| Q1 25 | $-148.9M | $20.3M | ||
| Q4 24 | $-85.2M | $26.0M | ||
| Q3 24 | $-84.8M | $20.8M | ||
| Q2 24 | $-58.2M | $11.4M | ||
| Q1 24 | $-120.7M | $15.7M |
| Q4 25 | $-69.4M | $14.4M | ||
| Q3 25 | $-76.9M | $5.9M | ||
| Q2 25 | $-99.9M | $7.3M | ||
| Q1 25 | $-149.7M | $13.9M | ||
| Q4 24 | $-86.2M | $13.2M | ||
| Q3 24 | $-86.1M | $10.8M | ||
| Q2 24 | $-59.2M | $9.0M | ||
| Q1 24 | $-123.2M | $14.6M |
| Q4 25 | -301.6% | 36.6% | ||
| Q3 25 | -558.2% | 14.9% | ||
| Q2 25 | -701.0% | 21.0% | ||
| Q1 25 | -900.1% | 32.7% | ||
| Q4 24 | -669.4% | 33.8% | ||
| Q3 24 | -945.2% | 36.1% | ||
| Q2 24 | -850.9% | 34.5% | ||
| Q1 24 | -425.7% | 48.1% |
| Q4 25 | 0.5% | 43.8% | ||
| Q3 25 | 0.2% | 48.6% | ||
| Q2 25 | 1.7% | 45.2% | ||
| Q1 25 | 4.4% | 15.0% | ||
| Q4 24 | 7.6% | 32.9% | ||
| Q3 24 | 14.0% | 33.3% | ||
| Q2 24 | 14.5% | 9.4% | ||
| Q1 24 | 8.7% | 3.7% |
| Q4 25 | — | 1.46× | ||
| Q3 25 | — | 1.58× | ||
| Q2 25 | — | 1.17× | ||
| Q1 25 | — | 1.56× | ||
| Q4 24 | — | 1.48× | ||
| Q3 24 | — | 0.82× | ||
| Q2 24 | — | 1.30× | ||
| Q1 24 | — | 1.41× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
NTLA
| Avencell Therapeutics Inc | $21.0M | 91% |
| Other | $1.0M | 4% |
| Avencell | $1.0M | 4% |
SD
| Oil Reserves | $19.0M | 48% |
| Natural Gas Reserves | $11.6M | 30% |
| Natural Gas Liquids Reserves | $8.7M | 22% |
